Experience shapes our research.
Our research draws on almost 30 years of life sciences equity research experience, including extensive international sell-side work. Led by Chris Kallos, Bridge Life Sciences specialises in ASX-listed small and mid-cap biotechnology, medical technology and healthcare companies.
We bring scientific understanding, commercial analysis and valuation together to explain the investment case at every stage of development. Our experience helps us identify the evidence, assumptions and milestones that matter, while keeping the risks and uncertainties in view.


